Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron

Jacquelyn M. Powers, Mark Shamoun, Timothy L. McCavit, Leah Adix, George R. Buchanan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). Study design In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. Results A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. Conclusion FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.

Original languageEnglish (US)
Pages (from-to)212-216
Number of pages5
JournalJournal of Pediatrics
Volume180
DOIs
StatePublished - Jan 1 2017

Fingerprint

Iron-Deficiency Anemias
Iron
Electronic Health Records
Intravenous Infusions
Hemoglobins
Cohort Studies
Retrospective Studies
ferric carboxymaltose
Therapeutics
Population

Keywords

  • heavy menstrual bleeding
  • inflammatory bowel disease
  • menorrhagia
  • nutritional

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron. / Powers, Jacquelyn M.; Shamoun, Mark; McCavit, Timothy L.; Adix, Leah; Buchanan, George R.

In: Journal of Pediatrics, Vol. 180, 01.01.2017, p. 212-216.

Research output: Contribution to journalArticle

@article{c5f63817aee04b6781ed738bf7b4c232,
title = "Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron",
abstract = "Objective To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). Study design In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. Results A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84{\%}) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. Conclusion FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.",
keywords = "heavy menstrual bleeding, inflammatory bowel disease, menorrhagia, nutritional",
author = "Powers, {Jacquelyn M.} and Mark Shamoun and McCavit, {Timothy L.} and Leah Adix and Buchanan, {George R.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jpeds.2016.09.053",
language = "English (US)",
volume = "180",
pages = "212--216",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron

AU - Powers, Jacquelyn M.

AU - Shamoun, Mark

AU - McCavit, Timothy L.

AU - Adix, Leah

AU - Buchanan, George R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). Study design In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. Results A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. Conclusion FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.

AB - Objective To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). Study design In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. Results A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions. Conclusion FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.

KW - heavy menstrual bleeding

KW - inflammatory bowel disease

KW - menorrhagia

KW - nutritional

UR - http://www.scopus.com/inward/record.url?scp=85006175128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006175128&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2016.09.053

DO - 10.1016/j.jpeds.2016.09.053

M3 - Article

VL - 180

SP - 212

EP - 216

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

ER -